Rallis Chris A's Form 4 filing
Fennec Pharmaceuticals Inc. (FENC) · filed Jul 8, 2024
- Accession no.
- 0001415889-24-019332
- Filed
- Jul 8, 2024
- Trade date
- Jul 5, 2024
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $7.07K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Rallis Chris ACIK 0001185945 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 5, 2024 | Common Shares | MOption exerciseAcquired | +1,792 | $2.79 | +$4,999.68 | 47,630 | Direct | |
| Jul 5, 2024 | Common Shares | SSaleDisposed | −1,173 | $6.03 | −$7,073.19 | 46,457 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 5, 2024 | Options | MOption exerciseDisposed | −1,792 | $2.79 | −$4,999.68 | 179,802 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.